Hyloris PHARMACEUTICALS

Reformulating the Future

New Product Candidate – HY-083

22 November 2022

Forward-Looking Statements

This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, “presentation” means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person’s organization or firm) or published for any purpose or under any circumstances.

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, “forward-looking statements” which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company.

Hyloris PHARMACEUTICALS

Rethinking, Reinventing, Optimising Existing Medications

To improve overall therapy outcomes

REFORMULATING

Changing dose and/or route of administration

REPURPOSING/
REPOSITIONING



New therapeutic uses

For the benefit of patients, physicians, payors

Hyloris PHARMACEUTICALS

To Drive Continuous Growth and Create Shareholders' Value

Acquisition and in-licensing of product candidates based on

- Clear scientific and medical rationale based on physicians'input
- Approved, well-known molecules
- Clear regulatory pathway
- Landscape review & patent protection
- Addressable market need
- Added value to the healthcare system



Continuously growing diversified product portfolio characterised by

- Fast market adoption
- Maximized ROI
- Addressing clear unmet needs
- Large potential

Ambition to become a leader in value-added medicines

Hyloris PHARMACEUTICALS

Broad, Innovative Portfolio*: Expand to ~30 Assets before 2025

Product	Route of Administration	Indication	Formulation and Manufacturing	Clinical Development	Regulatory Filing	Target Market
CARDIOVASCULAR (CV) PORTFOLIO			**Up to 7 years**			
Sotalol IV	IV	Atrial fibrillation	*Launched in U.S./partnered with AltaThera*			
Aspirin IV U.S.	IV	Acute coronary syndrome				
Milrinone	Extended Release Capsule	Advanced heart failure (LVAD)				
Dofetilide IV	IV	Atrial fibrillation				
Metolazone IV	IV	Congestive heart failure				
HY-074	IV	Acute coronary syndrome				
HY-075	Oral Liquid	Coronary heart disease				
OTHER VALUE-ADDED PORTFOLIO			**Up to 7 years**			
Maxigesic® IV	IV	Post-operative pain	*Licensed in >100 countries/partnered with AFT Pharmaceuticals*			
HY-004	Oral Liquid	Specific dental indication				
Miconazole-DB	Topical	Severe and rVVC				
Plecoid™ Agent	IV	AML/SCLC				
Alenura™	PFS	IC / PBS				
Atomoxetine	Oral Liquid	ADHD				
HY-029	Oral Liquid	Viral infection				

Our high barrier generic products, TXA RTU, HY-038, HY-016 and Fusidic Acid Cream have not been included in the above overview

Intended to be commercialised by Hyloris in the U.S.
Intended to be commercialised with partner

Hyloris PHARMACEUTICALS

Aspirin IV U.S. is formerly known as HY-073
IV: intravenous ; RTU: ready to use; IM: intra-muscular

LVAD: battery-operated, mechanical surgically implanted pump, which helps the left ventricle of the heart pump blood TXA: tranexamic acid; ADHD: attention deficit hyperactivity disorder; Miconazole-DB: miconazole-domiphen bromide ; rVVC: recurring vulvovaginal candidiasis; AML: Acute Myeloid Leukemia; SCLC: Small cell Lung Cancer

Product Candidate HY-083

Nasal Spray in the treatment of Idiopatic Rhinitis



Hyloris PHARMACEUTICALS

Disease overview

Chronic rhinitis is best defined by the long term presence of two or more of the three following nasal symptoms: **sneezing, runny nose, stuffy nose**.

Idiopathic rhinitis is chronic rhinitis with **no identifiable cause**, and thus an absence of preferred treatment: trial and error.

It originates from an overexpression of TRPV1-receptors on **sensory nerves in the nose**, which sense changes in temperature, humidity or environmental triggers.

Discovery of TRPV1-receptors was awarded the **2021 Nobel Prize** in Physiology & Medicine.

- Estimated to affect around 7% of the adult population in the USA , incidence is on the rise
- If left untreated, the condition can increasingly impact quality of life
  Interrupted sleep
  Drowsiness in the daytime
  Irritability
  Poor concentration
- Patients usually wait ~8 years before seeing a specialist

Diagnosis and treatment pathway

Trial and error approach leads to unnecessary surgery

	Infectious Rhinitis	Allergic Rhinitis	Non-Allergic Non-infectious Rhinitis
Presentation	Discolored secretions Crusting	Positive skin-Prick-Test Specific IgE in serum	No sign of sensitization
Patient identification			→ Geriatric → Gustatory → Occupational → Hormone-induced → Drug-induced → **Idiopathic rhinitis** Patient history **Per exclusion**
Available treatments	Anti histamines Nasal cortocoids Decongestants (oral/intranasal)	**FIRST LINE CARE** General practitioner Pharmacy **SPECIALIST CARE** Rhinologist	**Mild to moderate** Conservative treatments Saline nasules **Severe** Turbinate reduction surgery

Hyloris PHARMACEUTICALS

Patient population and addressable market

~35% of the population is suffering from **Chronic Rhinitis**

- **Infectious rhinitis**
- **Allergic rhinitis**
- **25-50%** **Non-allergic Rhinitis**
  - **Inflammatory rhinitis**
  - **Other causes**
    Gustatory, drug-induced, ...
  - **Idiopathic rhinitis**
    7% of the population
    50-70%
    - **Seeks specialist treatment**
      Inconsistent results
      13%

Addressable market
~19 million patients in the US
~25.8 million patients in Europe

Hyloris PHARMACEUTICALS

Rationale for HY-083 and unmet need

> Patients are typically subjected to multiple rounds of treatment failures that lead to frustration towards seeking medical care and medication use.

Significant increase of risk of other comorbid conditions
Obstructive sleep apnea, fatigue, headache, malaise, poor appetite, weakness

Children at risk for permanent facial changes from untreated rhinitis
Increased facial length, retrognathic maxilla and mandible, and dental malocclusions from obstructed breathing

Poor Quality of Life

Impaired work performance in adults
Can also manifest as learning disabilities, behavioral, and psychological effects in children

Additional expenditures and lost time from work
Doctor appointments, medication prescriptions

HY-083 aims to provide significant improvement and increase patient quality of life:

- ✓ New treatment where currently there is none
- ✓ Significantly minimize symptoms of Idiopathic Rhinitis
- ✓ Can avoid surgical treatment for many patients
- ✓ Reduces total overall treatment cost for this group of patients
- ✓ Low investment / Volume product
- ✓ In line with selection criteria (unmet medical need, 7 years & €7 million)

Hyloris PHARMACEUTICALS

Potential Game Changer, Geared for Growth

MULTIPLE SHOTS ON GOAL

≤ 7 years to market

≤ €7 million average cost to market

Lower risk as we start from existing drugs

15[1] Innovative, patented, value-added drug candidates in the pipeline

COMMERCIAL PORTFOLIO

2 patented products with partners

Addressing unmet needs

Build **U.S. commercial** team

Relevant improvements for patients, physicians and the healthcare system

Ambition to become the reference in value-added medicines over the coming years with 30 assets before 2025

[1] 13+2 commercialised products, excluding our high barrier generic products, TXA RTU, HY-038, HY-016 and Fusidic Acid Cream.

Hyloris PHARMACEUTICALS

Anticipated Value Inflection Milestones in the next 12 months

Clinical

- Starting pivotal PK clinical trial for Dofetilide IV and HY-029
- Starting Phase 2 clinical trial for Alenura™
- Completing Phase 2 clinical trial recruitment for Miconazole-DB end of 2022. Top line results in H1 2023.
- Other PK study in preparation
- Starting Phase 3 clinical trial on HY-004 (Tranexamic Acid Oral Mouth Rinse)

Regulatory

- Atomoxetine: implementing changes to taste masking technology – FDA scientific feedback
- Additional E&L study ongoing for Maxigesic® IV – FDA submission upon completion of E&L study

Commercial

- Commercial partnership(s)
- Continued roll-out of Maxigesic® IV and Sotalol IV with our partners

Finance

Cash position H1 2022: €57,7m

Hyloris PHARMACEUTICALS

Hyloris PHARMACEUTICALS

Q&A